A clinical-stage biopharmaceutical company developing targeted precision medicines for solid tumors and blood cancers. Its investigational drug tipifarnib and approved oral medicine ziftomenib (KOMZIFTI) treat acute myeloid leukemia and other cancers, used by patients who have few other options. Founded in 2014, the company takes its name from the Kura River in southwestern Asia, a nod to the river-themed naming of its founders' earlier firm, Araxes Pharma — chosen because the Kura eventually flows into the Araxes, symbolizing drugs that work "downstream" of the RAS cancer pathway.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -288.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.